The Efficacy of Efavirenz 400 mg with two Nucleoside reverse transcriptase inhibitor in virologically suppressed adult HIV-infected patients in Prapokklao hospital
Article Sidebar
Main Article Content
Abstract
Background: Efavirenz (EFV) is one of the core drugs for therapy in cases of HIV infection. The standard dose is 600 mg once daily. EFV has many side effects related to high drug levels in the blood. Therefore, reducing the dose of EFV can cause fewer side effects. Previous studies found that treatment with EFV 400 mg resulted in virological suppression with fewer side effects.
Objective: To study the efficacy of an EFV 400 mg once daily regimen in virologically suppressed adult HIV-infected patients (Viral load < 50 copies/mL).
Methods: In this retrospective study, we recruited adult HIV-infected patients who attended the Infectious Diseases Clinic, Prapokklao Hospital, during 2015 and had virological suppression through EFV 600 mg once daily which was later adjusted to EFV 400 mg once daily. The HIV viral load was collected yearly until 2018 to evaluate the efficacy.
Results: 357 patients were enrolled. 317 patients received EFV 400 mg once daily, Lamivudine 300 mg once daily, and Tenofovir 300 mg once daily. 40 patients received EFV 400 mg once daily with other two NRTIs. 350 patients (98%) had an HIV viral load less than 200 copies/mL and 345 patients (96.6%) had an HIV viral load less than 50 copies/mL
Conclusion: Modification of EFV 600 mg once daily to EFV 400 mg once daily showed efficacy in virological control in virologically suppressed adult HIV-infected patients.
Article Details
References
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs treating and preventing HIV infection recommendations for a public health approach. 2 nd ed. Geneva: World Health Organization; 2016.
Mylan Pharmaceuticals Inc. Efavirenz [Internet]. 2015[cited 2017 Oct 20]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2016/091471Orig1s000lbl.pdf.
Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 2010;6:95-103.
Poeta J, Linden R, Antunes MV, Real L, Menezes AM, Ribeiro JP et al. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals. J Antimicrob Chemother 2011;66:2601-4.
Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 2014;383(9927): 1474-82.
Lanzafame M, Bonora S, Lattuada E, Vento S. Efavirenz dose reduction in HIV-infected patients. HIV Med 2012;13:252-3.
van der Lugt J, Avihingsanon A. Clinical pharmacology and pharmacokinetics of antiretrovirals in Asia. Asian Biomedicine 2009; 3:53-62.